logo
Aspergillosis information home
  • Browse information
    • Finding your way around
  • Latest Articles
  • For Professionals
  • Search

Aspergillosis Research Update – 18 November 2026

November 16, 2026
|In Patient Newsletter, Professional Newsletter, Research Summaries, Weekly Updates
|By GAtherton
Person reading a patient-friendly aspergillosis research update with lung, laboratory and fungal research illustrations.
Recent aspergillosis research explained for patients, carers and non-specialists.

New research on biologic treatments for ABPA, antifungal resistance, aspergillosis after tuberculosis and treatment of serious fungal infections.

This week’s research brings encouraging findings for people with asthma and allergic bronchopulmonary aspergillosis (ABPA), alongside important developments in our understanding of antifungal resistance and the diagnosis and treatment of aspergillosis.

We have selected five important publications from the latest literature search, with particular attention to what the findings might mean for patients and their families.

Key findings this week

  • Biologic treatments and ABPA: Having ABPA was not associated with a statistically significant increase in asthma exacerbations during the year after starting biologic treatment.
  • Antifungal resistance: New research suggests that resistance to azole antifungal medicines in some black Aspergillus species may develop through environmental exposure.
  • Aspergillosis after tuberculosis: A study highlights the importance of considering chronic pulmonary aspergillosis (CPA) in people with persistent respiratory symptoms following TB.
  • Fungal infections of the brain: Researchers review evidence that isavuconazole can reach infected brain tissue, even when concentrations in spinal fluid are low.
  • Diagnosing aspergillosis in COPD: A scientific exchange highlights the continuing difficulty of distinguishing fungal colonisation from clinically significant infection.

Paper of the Week: Biologic treatments for asthma in people with ABPA

Nasrullah A, et al. – Clinical & Experimental Allergy, 16 November 2026

Biologic medicines have become increasingly important in treating severe asthma. Some are also used in selected patients with ABPA, particularly when conventional treatment has not provided adequate control or when repeated courses of oral corticosteroids are needed.

But does having ABPA affect how well biologic treatment works for asthma?

Researchers compared outcomes in patients starting biologic treatment for asthma, with and without an additional diagnosis of ABPA.

Their main analysis found no statistically significant difference in the risk of asthma exacerbations over the following year between the matched groups.

Additional analyses produced consistent findings, although exploratory results involving steroid use and pneumonia require caution.

Why does this matter?

People with ABPA often have more complicated respiratory disease, so it is encouraging that an ABPA diagnosis was not associated with a clearly worse asthma exacerbation outcome after starting biologic treatment.

However, this does not prove that all biologics are equally effective, or that successful asthma treatment necessarily controls ABPA itself.

The study adds to the growing evidence supporting careful consideration of biologic therapies in patients with complex allergic airway disease.

Read the research: Clinical Outcomes After Biologic Initiation in Asthma With and Without Allergic Bronchopulmonary Aspergillosis.

2. Can antifungal resistance develop in the environment?

Punt M, et al. – Journal of Infection, 14 November 2026

Azole antifungal medicines are important treatments for several forms of aspergillosis. Unfortunately, some Aspergillus fungi are becoming less susceptible to these medicines.

Most research on environmental azole resistance has concentrated on Aspergillus fumigatus. This new study investigates members of Aspergillus series Nigri, a group that includes several black aspergilli.

The researchers examined clinical and environmental isolates and identified reduced azole susceptibility in some of them. The findings raise the possibility that environmental selection contributes to resistance in these species.

Importantly, resistant Aspergillus tubingensis was also identified in patients without previous exposure to mould-active azole treatment.

Why does this matter?

Patients sometimes assume that antifungal resistance develops only after prolonged treatment.

This research reinforces an important distinction: resistant fungi may already exist in the environment before a patient becomes infected.

It also highlights why identifying the fungal species and performing susceptibility testing can be important when treatment is difficult or resistance is suspected.

The findings do not establish that environmental exposure caused resistance in individual patients, but they suggest that this route deserves further investigation.

Read the research: Azole resistance in Aspergillus series Nigri and possible link with environmental selection route.

3. Recognising chronic pulmonary aspergillosis after tuberculosis

Gupta VB, et al. – Monaldi Archives for Chest Disease, 9 November 2026

Tuberculosis can leave permanent changes in the lungs, including cavities and damaged tissue. These changes can create conditions in which Aspergillus establishes a persistent infection.

Researchers in eastern India investigated 280 people with previous tuberculosis and residual abnormalities on chest imaging.

They reported that approximately 27.5% met the study criteria for chronic pulmonary aspergillosis (CPA).

This was a selected group of symptomatic patients attending a specialist hospital, so the figure should not be interpreted as the prevalence of CPA among everyone who has recovered from tuberculosis.

Why does this matter?

CPA can produce symptoms similar to those of tuberculosis, including persistent cough, fatigue, weight loss and sometimes coughing up blood.

Without appropriate investigation, CPA may remain unrecognised or be mistaken for recurrent tuberculosis.

The study reinforces the importance of considering CPA when respiratory symptoms continue after TB treatment, particularly where chest imaging shows cavities or other persistent abnormalities.

Tests for Aspergillus-specific IgG antibodies can be useful as part of the diagnostic assessment.

Read the research: Prevalence and clinical correlates of chronic pulmonary aspergillosis among symptomatic post-tuberculosis patients.

4. Isavuconazole and fungal infections of the brain

Cavassin FB, et al. – Medical Mycology, 10 November 2026

Invasive aspergillosis can occasionally spread to the central nervous system, producing a serious and potentially life-threatening infection.

Treating these infections is particularly difficult because antifungal medicines must reach the affected tissues.

This review examines the available evidence for isavuconazole, including its penetration into brain tissue and reported clinical outcomes.

An important observation is that concentrations measured in cerebrospinal fluid may be much lower than those found in infected brain tissue.

Why does this matter?

Drug concentrations in spinal fluid do not necessarily tell us how much medicine reaches an infection within the brain itself.

This distinction may help specialists interpret pharmacological evidence when selecting treatment for complex fungal infections.

However, the clinical evidence remains limited. The review does not establish that isavuconazole is superior to other antifungal treatments, such as voriconazole.

Read the research: Isavuconazole in the management of central nervous system fungal infections: Parenchymal penetration and clinical performance.

5. How should aspergillosis be diagnosed in people with COPD?

Gong B; Denning DW, Rogers TR and Vestbo J – American Journal of Respiratory and Critical Care Medicine, 12 November 2026

Two recently published letters address the validation of diagnostic criteria for aspergillosis in people with chronic obstructive pulmonary disease (COPD).

This is an important clinical problem because Aspergillus can sometimes be detected in respiratory samples without necessarily causing invasive infection.

Doctors must therefore interpret microbiological findings alongside symptoms, imaging, underlying lung disease and other evidence.

Why does this matter?

A positive fungal test does not always mean that antifungal treatment is required.

Equally, serious aspergillosis must not be overlooked simply because a patient already has COPD or another explanation for their respiratory symptoms.

The correspondence illustrates the importance of carefully validated diagnostic criteria. As these are scientific letters rather than new clinical trials, their specific arguments require consideration alongside the original diagnostic research.

Read the correspondence: Beyond Diagnostic Yield: Validating Aspergillosis Criteria in COPD and Reply to Gong.

Other research this week

Invasive fungal infections following stem-cell transplantation

A study examined the incidence and risk factors for invasive fungal infections in patients with moderate or severe chronic graft-versus-host disease. These patients can be particularly vulnerable because of immune dysfunction and immunosuppressive treatment.

Read the research – Rodriguez-Rodriguez et al.

ABPA and tropical pulmonary eosinophilia

Researchers investigated the coexistence of two conditions associated with raised eosinophil counts in an area where filarial infections are endemic. The findings underline the importance of considering different causes of eosinophilic lung disease.

Read the research – Ejazi et al.

Isavuconazole in a newborn with disseminated aspergillosis

A case report describes off-label antifungal treatment in a neonate with high-risk congenital leukaemia. Such reports are valuable in rare clinical situations but cannot establish general treatment effectiveness or safety.

Read the research – Alfarano et al.

What does this mean for people living with aspergillosis?

Three messages stand out this week.

First, treatment options continue to develop. The study of biologic therapy in asthma and ABPA offers some reassurance that patients with ABPA may not experience worse asthma exacerbation outcomes after starting these medicines.

Second, accurate diagnosis remains essential. Whether investigating persistent symptoms after tuberculosis or interpreting fungal tests in COPD, the presence of Aspergillus must be considered in the wider clinical picture.

Third, antifungal resistance remains an important challenge. Research into environmental resistance reminds us that successful treatment depends not only on choosing an antifungal medicine but also on understanding the organism being treated.

Take-home messages

Research continues to improve our understanding of aspergillosis, but individual studies rarely change clinical practice immediately.

This week’s papers offer encouraging findings about biologic treatment, highlight the need to recognise CPA after tuberculosis, and expand our understanding of antifungal resistance and complex infections.

For patients, the most important message remains that treatment should be tailored to the individual, with specialist advice when disease is difficult to diagnose or control.


This research update is prepared for patients, carers and interested readers by the National Aspergillosis Centre’s patient information service. Papers were identified through biomedical literature searches and selected evidence was checked using scite. Some summaries are based on abstracts rather than complete full-text review. Research findings are provided for information and should not be used to change prescribed treatment without medical advice.

Print Friendly, PDF & Email

Share this post

Path: Start » Patient Newsletter » Aspergillosis Research Update – 18 November 2026
Print Friendly, PDF & Email

Did this page help you?

Tell us in one minute

Related information

Infographic explaining when patients taking Gaviscon, Adcal, omeprazole, steroids, antifungals and antibiotics should ask a pharmacist for advice about medication timing and interactions.

Taking Gaviscon, Omeprazole, Adcal, Steroids and Antifungals: A Practical Medication Guide

November 17, 2026

Illustration of an aspergilloma inside a lung cavity, surgical removal of the affected area, and follow-up care.

Can surgery cure an aspergilloma?

November 16, 2026

Patient comparing blue reliever inhaler and combination AIR MART inhaler for asthma and aspergillosis

Blue inhalers, combination inhalers and aspergillosis: what patients need to know

November 16, 2026

Illustration of children walking to school past an electric car charging beside homes with solar panels.

Cleaner air, healthier childhoods: reasons for hope

November 13, 2026

Browse all information hubs
Please read our health information notice before using this website to make decisions about your health. Find your way around this website ¦ Contact & Support ¦ About This Website ¦ Editorial Policy ¦ Funding and Independence ¦ Privacy ¦ Cookies ¦ Accessibility ¦ Responsible Disclosure ¦ Newsletter ¦ Health information notice ¦ Editorial standards
© 2026 Aspergillosis Patients & Carers Support. All rights reserved